HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Temporary Funding For US Agencies Delays $5M For FDA’s Cannabidiols Regulatory Pathway Work

Executive Summary

Senate on 29 September was expected to a pass a CR the House passed a week earlier to fund FDA and other federal departments and agencies through 11 December.

You may also be interested in...



Senate Appropriators Ask USDA To Remove Business ‘Roadblocks’ In Hemp Production Rule

Senate committee “is concerned” USDA's interim final rule “creates roadblocks for farmers” by imposing short timeframes for testing harvested hemp for levels of THC  in crops and requiring testing only by DEA-registered labs.

Senate Appropriators Press FDA On Acetaminophen Dosing, Pass On Expanding Drug Recall Authority

Senate Appropriations Committee has bills for federal agencies’ FY2021 budgets. The committee, which also published each subcommittee’s report accompanying its appropriation legislation, has not scheduled hearings to vote on the bills.

If Safety Data Open Door In US, Cannabinoids’ Lawful Use In Supplements At Least A Year Off

At FDLI annual meeting, attorneys cast doubt on CBD rules outlook. Paul Joseph says regulations are at least a year away while Jonathan Havens doubts FDA is even working on regulations, including GMPs, because it is still asking industry for specific safety details.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150519

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel